基于风险分层的MRI方案检测临床显著前列腺癌
该回顾性研究纳入390例疑似临床显著前列腺癌(csPCa)男性患者,按Rotterdam前列腺癌风险计算器评分分为低、中、高风险组,比较三种MRI方案(mpMRI、非增强MRI、简化MRI)的诊断性能和临床效用。结果显示,在中风险组mpMRI灵敏度更高且活检效率更优,而低风险和高风险组方案间差异有限,支持基于风险选择MRI方案。
要点
- 中风险患者采用mpMRI可提高csPCa检出灵敏度(83% vs 简化MRI 62%)和活检效率。
- 低风险患者简化MRI灵敏度最高(95%),且安全避免活检的潜力最大。
- 高风险患者三种MRI方案诊断性能差异无统计学意义。
局限性
- 回顾性研究设计
- 单中心研究
- 样本量390例,各风险亚组样本量较小
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To compare the diagnostic performance and clinical utility of three MRI protocols for detecting clinically significant prostate cancer (csPCa) according to prebiopsy risk. Materials and Methods This retrospective study included 390 male patients who underwent prostate multiparametric MRI (mpMRI) between January 2019 and April 2024 for suspected csPCa, followed by biopsy. Patients were stratified by Rotterdam Prostate Cancer Risk Calculator score into low-risk (<4%), intermediate-risk (4%-9%), and high-risk (≥10%) groups. Three datasets were generated from each examination: mpMRI (T2-weighted imaging, diffusion-weighted imaging [DWI], and dynamic contrast-enhanced imaging), unenhanced MRI (multiplanar T2-weighted imaging and DWI), and short MRI (axial T2-weighted imaging and DWI). Overall, 1170 datasets were randomly assigned to 10 expert radiologists (117 examinations each). Diagnostic performance for grade group 2 or greater cancer and clinical utility metrics were compared across risk groups. Results Among the 390 patients (median age, 66 years [IQR, 61-71 years]), csPCa prevalence was 34.4% (134 of 390). In low-risk patients, short MRI demonstrated the highest sensitivity (95% [21 of 22]), with no significant differences among protocols (all P ≥ .21) and greatest potential for safe biopsy avoidance (84 biopsies avoided per missed csPCa). In intermediate-risk patients, mpMRI showed higher sensitivity (83% vs 72% for unenhanced MRI and 62% for short MRI; P = .012 for mpMRI vs short MRI) and higher biopsy efficiency (1.11 vs 0.85 for mpMRI vs unenhanced MRI). In high-risk patients, protocol-related differences were minimal (all P ≥ .12). Conclusion mpMRI was associated with improved sensitivity and biopsy efficiency in intermediate-risk patients, whereas protocol differences were limited in low- and high-risk groups; these findings support risk-adapted selection of MRI protocols. Keywords: MR-Dynamic Contrast-enhanced, MR Imaging, Urinary, Prostate, Neoplasms-Primary, Efficacy Studies, Prostatic Neoplasms, MRI, Contrast Medium, Biopsy, Risk Assessment Supplemental material is available for this article. © RSNA, 2026.
引用
- Ponsiglione A, Cereser L, De Martino M, et al. Risk-adapted MRI Protocols for the Detection of Clinically Significant Prostate Cancer. Radiol Imaging Cancer. 2026. PMID: 42886040. doi:10.1148/rycan.260124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。